Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often...
Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) )
Also on site :
- Bodies of two Israeli-American hostages recovered from Gaza in joint military operation
- Second interview with AUC professor Bahgat Korany discusses Suez Canal, GERD concerns & global politics
- Philadelphia Cream Cheese Shakes Up Classic Recipe With Limited-Edition Offer